MarketsandMarkets

OncoGene 2023

09th-10th March 2023

ILEC Conference Centre & Ibis London Earls Court, London

EVENT OVERVIEW

With the advent of new technological advancements in medical research and diagnostic strategies, early disease diagnosis and prevention has witnessed a medical revolution. We are proud to present to you our ‘OncoGene’ ConfEx in London scheduled on 9th – 10th March 2023. This ConfEx is an assemblage of 3 inextricably linked conferences like 7th Annual Next-Gen Immuno-Oncology Conference, Next-Gen Genomics and Proteomics Conference and Precision Medicine Conference which will accommodate diverse sessions on cutting edge discussions via Presentations, Exhibitions, Speaker QnAs, Panel discussions or Breakout sessions.

Tag Line
Next-Gen Immuno-Oncology Immuno-Oncology Cancer Biomarkers Cancer Genetics Cell and Gene Therapy Immunology Immunotherapy Tumor Biology Antibody Development Oncolytic Viruses Immune Checkpoint Inhibitors
Tag Line
Next-Gen Genomics  & Proteomics Genomics|Proteomics Computational Biology Structural Biology Functional Genomics Mass Spectrometry Liquid Chromatography Multi-Omics Science Protein Science Translational Biology
Tag Line
Precision Medicine Personalized Medicine Digital Biomarkers Complex | Chronic | Rare Disease Genome Sequencing Artificial Intelligence and Machine Learning Translational Medicine Genomic Medicine Molecular Medicine Drug Discovery

The ConfEx aims to bring together the full spectrum of experts, leaders and shareholders from global pharmaceutical organizations, biotech and therapeutical companies, and internationally eminent research and academic institutions to share broad perspective on advancements and solutions to most critical challenges in the areas of Immuno-Oncology, Advancements in Genomics and Proteomics and Personalized Medicine Approaches.

The eagerly anticipated ConfEx is intended to have interactive sessions on the application of each area in complex disease prediction, quantitative analysis of genomic and proteomic tools and federal efforts in developing the hyperindividualized therapy. The discussion also encompasses the latest advantages of clinical data,digitalization in healthcare and dynamic therapeutic innovations.

CO-LOCATED CONFERENCES

MarketsandMarkets Precision Medicine Conference
7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
MarketsandMarkets Next-Gen Genomics and Proteomics Conference

WHAT TO EXPECT

  1. Use of digital biomarkers for drug development, Multi-Omics prospects (Epigenomics, Proteomics, Transcriptomics, Pharmaco genomics)
  2. Inception of technologies for Precision Medicine – Impact of big data, Artificial intelligence, and Machine Learning, Insilico trials for Precision medicine
  3. Cost benefit issues, Regulatory, Ethical and Social challenges in Precision Medicine
  4. Updates in development of ADC’s and Bispecific Ab’s
  5. Immune Checkpoint Inhibitors and Combinations
  6. CAR-T Cell therapy, TCR Based-Cell Therapy
  7. Tumor microenvironment and Oncolytic Viruses
  8. Gene Expression and Molecular Mechanism in Immune Signaling, Flow Cytometry in Immune Phenotyping, Polygenic Risk Scores for Immuno Metabolic Markers
  9. Electrospray Mass Spectrometry based Biomarkers, Development of Multidimensional Liquid Chromatography, Spatial Profiling in Tumor Proteomics
  10. Advances in Genome Wide Variant Data and Application of Omics in Protein – Protein interaction

  • Witness live action how precision medicine is revolutionizing the future of healthcare
  • Quality insights and cohesiveness of key issues and obstacles experienced by the healthcare providers while implementing precision medicine
  • Discover the different avenues in patient centric care
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Comprehend the current and future research avenues in drug discovery using Genomics and Proteomics
  • Discuss the emerging technologies and opportunities with cutting edge strategies
  • Opportunity for one-on-one networking with the delegates and extend professional competency

  • Industry: Pharma/Therapeutic Companies/Start Up’s
  • CEOs, CMO’s, CSO’s, COO’s, Presidents, Vice Presidents, Directors, Managing Directors, Head of Departments, Executive Leaders, Pharmacists, Oncologists, Geneticists, Bioinformatician, Protein Scientist, Principal Scientists, Big Data Scientists, Business Development, Regulatory and Policy Advisors, Diagnostic Laboratory Professionals, Global Leaders.
  • Departments: Genomics, Proteomics, Oncology, Molecular Biology, Genetics Bioinformatics, Computational Biology, Protein science, Pharmacogenomics, Biotechnology, Data Science
  • Academics: Universities, Research Institutes, Hospitals
  • Head of Departments, Professors, Lecturers, Senior Scientists, Researchers, Bioinformaticians
  • Departments: Genomics, Proteomics, Oncology, Molecular Biology, Genetics Bioinformatics, Computational Biology, Protein science, Pharmacogenomics, Biotechnology, Data science

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Antibody Formats & Cellular Therapy

Keynote:

09:00 - 09:30

Solution Provider Presentation

09:30 - 10:00

Precision Medicine in IO-Case study

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

T-cell receptor signaling in Cancer Immunotherapy

11:15 - 11:45

Adoptive Cellular Therapy

11:45 - 12:15

Targeting cancer with ADC’s-Case study

12:15 - 12:45

Development of bispecific antibodies for cancer therapy

12:45 - 13:15

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Challenges in the nonclinical development of mAb-based cancer immunotherapy

14:15 - 14:45

Dendritic cell therapy in IO

14:45 - 15:15

Solution Provider Presentation

15:15 - 15:45

Afternoon Refreshments and Poster Presentations | One-to-One Networking Meetings

15:45 - 16:30

Engineering CAR T cells for enhanced efficacy and specificity

16:30 - 17:00

Solution Provider Presentation

17:00 - 17:30

Choosing IO in multiple myeloma-Case Study

17:30 - 18:00

Closing remarks from the Chairman

18:00 - 18:00

Quantum Leap in Global approach to Biomedicine

Systemic Implementation of Functional Genomics in Biomedicine

09:00 - 09:30

Interaction and Organellar Proteomics for Biomedicine

09:30 - 10:00

Solution Providers Presentation

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meeting

10:30 - 00:00

Genomics and Proteomics in System Biology Approach

Protein – DNA Interaction – Significant Role in Molecular and Cellular Mechanism

11:20 - 11:50

Applied and Translational Genomics in Systems Biology

11:50 - 12:20

Solution Providers Presentation

12:20 - 12:50

Lunch and Poster Presentation | One-to-One Networking

12:50 - 13:50

Future Expansion of Epigenomics in Systems Biology Research

14:50 - 14:20

Integration of Genomics and Proteomics in Immune Signalling

Proteo-Genomics and Immunopeptides

14:20 - 14:50

Advancement in Flow cytometry – Mainstay in Immune Phenotyping

14:50 - 15:20

Panel discussion –De Novo Analysis of Genomic/Transcriptomic datasets – Analysis of Variant Peptide

15:20 - 16:00

Evening Refreshments and Poster Presentation | One-to-One Networking

16:00 - 16:50

Investigating Gene Expression and Molecular Mechanism in Activation and Regulation of Immune Signaling

16:50 - 17:20

Quantum Leap in Global approach to Biomedicine

Solution Providers Presentation

17:20 - 17:50

Polygenic Risk Scores for Immuno-Metabolic Markers

17:50 - 18:20

Closing remarks by the Chairperson

18:20 - 18:20

Overview of precision medicine

‘Customizing Specific treatment to specific genomic characteristics of individuals’ – Overview of Precision Medicine

09:00 - 09:30

Quantum leap in Genomic Biology and Genomic Medicine

09:30 - 10:00

Solution Providers Presentation

10:00 - 00:00

Morning Refreshments and Poster Presentation | One-to-One Networking Meeting

10:30 - 11:20

Inception of technologies in precision medicine

Impact of Big data in Precision Medicine

11:20 - 11:50

New realm of precision medicine- Artificial Intelligence and Machine Learning

11:50 - 12:20

Solution Providers Presentation

12:20 - 12:50

Lunch and Poster Presentation | One-to-One Networking

12:50 - 13:50

In Silico Trials for Precision Medicine – Role of computational biology

13:50 - 14:20

Precision approaches to Tumor Oncology

Use of tumour-associated antigen targeting Humabodies to deliver CD137 agonism to the tumour microenvironment

Andrew Pierce

Andrew Pierce, Vice President, Translational Biology, Crescendo Biologics

14:20 - 14:50

Phage-guided delivery of nucleic acid therapeutics in oncology and other human diseases

Amin Hajitou

Amin Hajitou, Professor, Chair of Targeted Therapies, Imperial College of London

14:50 - 15:20

Solution Providers Presentation

15:20 - 15:50

Evening Refreshments and Poster Presentation | One-to-One Networking

15:50 - 16:50

Future Purview of Precision Medicine

Use of AI and machine learning algorithms to provide rapid and accurate antibiotic susceptibility testing, tackling antimicrobial resistance one test at a time

Stuart Hannah

Stuart Hannah, CEO, Microplate Dx Ltd

16:50 - 17:20

Solution Providers Presentation

17:20 - 17:50

State of the art – Digital health in Precision Medicine

17:50 - 18:20

Closing remarks by the Chairperson

18:20 - 18:20

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Immune Checkpoints, Biomarker and Tumour Microenvironment

Keynote:

09:00 - 09:30

Solution Provider Presentation

09:30 - 10:00

Role of Tumour Micro-Enviroment in Oncolytic Viral Therapy

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation

11:15 - 11:45

New IO Combination therapies and Biomarkers

11:45 - 12:15

Next-generation checkpoints beyond PD-1 and CTLA-4

12:15 - 12:45

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Combining oncolytic viruses with immune checkpoint inhibitors

14:15 - 14:45

Solution Provider Presentation

14:45 - 15:15

Immunomodulation in IO

15:15 - 15:45

Closing remarks from the Chairman

15:45 - 15:45

Comprehensive Analysis of Quantitative Genomics

Next Generation Sequencing (NGS)- RNA sequencing/Microarray in Predisposition of Biomarkers in Rare diseases

09:00 - 09:30

Single Cell Sequencing using Circulating Tumor Cells in Disease Diagnosis

09:30 - 10:00

Morning Refreshments and Poster Presentation | One-to-One Networking

10:00 - 00:00

Application of Shotgun Proteomics in Diagnostics

Electrospray Mass Spectrometry based Biomarkers using Cell Proteomics

10:50 - 11:20

Solution Providers Presentation

11:20 - 11:50

Development of Multidimensional Liquid Chromatography – Application in Clinical Proteomics

11:50 - 12:20

Lunch and Poster Presentation | One-to-One Networking

12:20 - 13:20

Spatial Profiling – Advances and Digitization in Tumor Proteomics

13:20 - 13:50

Solution Providers Presentation

13:50 - 14:20

Afternoon Refreshments and Poster Presentation | One-to-One Networking

14:20 - 15:10

Changing Research in Omics Data

Advances in Genome Wide Variant Data

15:10 - 15:40

Application of Omics in Protein – Protein Interaction

15:40 - 16:10

Artificial Intelligence / Machine learning in Genomics and Proteomic Data Strategy

16:10 - 16:40

Closing remarks by the chairperson

16:40 - 16:40

Precision Medicine in Disease Prediction and Treatment

Achieving precision medicine in chronic diseases: from patientfocused drug discovery to personalized prediction, prevention, and treatment

Dr Steve Gardner

Dr Steve Gardner, CEO and Co-founder, PrecisionLife, UK

09:00 - 09:30

CAR T-cell immunotherapy of solid tumours: Parallel learning from the clinic and lab

John Maher

John Maher, Chief Scientific Officer, Leucid Bio

09:30 - 10:00

Morning Refreshments and Poster Presentation | One-to-One Networking

10:00 - 10:50

Precision Medicine and Pharmacogenomics

Using digital biomarkers for a precision medicine approach to neuroscience drug development

Jennifer Barnett

Jennifer Barnett , CEO, Monument Therapeutics

10:50 - 11:20

Solution Providers Presentation

11:20 - 11:50

Use of spatial transcriptomics to identify differentially expressed biological pathways in SEGA brain tumours from patients with Tuberous sclerosis complex

Hywel Williams

Hywel Williams, Senior Lecturer in Bioinformatics, School of Medicine, Division of Cancer and Genetics, Cardiff University

11:50 - 12:20

Lunch and Poster Presentation | One-to-One Networking

12:20 - 13:20

Panel discussion - No one marker for one cancer – evolution of markers in common cancers

13:20 - 13:50

Solution Providers Presentation

13:50 - 14:20

Afternoon Refreshments and Poster Presentation | One-to-One Networking

14:20 - 15:10

Comprehensive genomic profiling

Droplet Microfluidics for personalized cancer therapy

Christoph A. Merten

Christoph A. Merten, , École Polytechnique Fédérale de Lausanne (EPFL)

15:10 - 15:40

Large scale implementation of population wide polygenic risk scores

Manuel Corpas

Manuel Corpas, Scientific Director, Cambridge Precision Medicine

15:40 - 16:10

RNA activation in genetic and acquired diseases

Nagy Habib

Nagy Habib, Founder and Head of R&D, MiNA Therapeutics

16:10 - 16:40

Closing remarks by the Chairperson

16:40 - 16:40

CONFERENCE SPEAKERS

ADVISORS

Alex F Frangi

Alex F Frangi

Diamond Jubilee Chair in Computational Medicine & RAEng Chair in Emerging Technologies, University of Leeds & KU Leuven - Turing Fellow

Manuel Corpas

Manuel Corpas

Scientific Director, Cambridge Precision Medicine

Arunima Ghosh

Arunima Ghosh

Managing director Indivumed Inc VP, Clinical network, USA, Indivumed

Lahiri Kanth Nanduri

Lahiri Kanth Nanduri

Lead Scientific Officer, FlowCell

Mark Stern

Mark Stern

Senior Director, Head Clinical Genetics and Genomics, Bristol Myers Squibb

Kenneth Linton

Kenneth Linton

Professor of Protein Biochemistry, Queen Mary University of London

Ricardo Carreira

Ricardo Carreira

Associate Director - Proteomics, Immunocore

SPEAKERS

John Maher

John Maher

Chief Scientific Officer, Leucid Bio

Dr Steve Gardner

Dr Steve Gardner

CEO and Co-founder, PrecisionLife, UK

Jennifer Barnett

Jennifer Barnett

CEO, Monument Therapeutics

Christoph A. Merten

Christoph A. Merten

, École Polytechnique Fédérale de Lausanne (EPFL)

Andrew Pierce

Andrew Pierce

Vice President, Translational Biology, Crescendo Biologics

Hemant Dhamne

Hemant Dhamne

Head of Vector and CAR-T Cell Processing, Immuneel Therapeutics Pvt Ltd

Sabina Patel

Sabina Patel

Director, Diagnostic Expert, AstraZeneca

Milena Kalaitsidou

Milena Kalaitsidou

Principal Scientist, Instil Bio

Stuart Hannah

Stuart Hannah

CEO, Microplate Dx Ltd

Amin Hajitou

Amin Hajitou

Professor, Chair of Targeted Therapies, Imperial College of London

Hywel Williams

Hywel Williams

Senior Lecturer in Bioinformatics, School of Medicine, Division of Cancer and Genetics, Cardiff University

Nagy Habib

Nagy Habib

Founder and Head of R&D, MiNA Therapeutics

Arijit  Mukhopadhyay

Arijit Mukhopadhyay

Reader in Human Genetics, University of Salford

Mark Throsby

Mark Throsby

Chief Scientific Officer, Gadeta BV

John Bridgeman

John Bridgeman

Director, Discovery Research, Instil Bio

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

ILEC Conference Centre & Ibis London Earls Court, London

PAST EVENT GALLERY